{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:40:38Z","timestamp":1790458838953,"version":"4.1.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1001\/jamadermatol.2018.1610","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T19:34:58Z","timestamp":1530128098000},"page":"913","source":"Crossref","is-referenced-by-count":18,"title":["Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib"],"prefix":"10.1001","volume":"154","author":[{"given":"Marina","family":"Danilenko","sequence":"first","affiliation":[{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Stamp","sequence":"additional","affiliation":[{"name":"Biostatistics Research Group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah D.","family":"Stocken","sequence":"additional","affiliation":[{"name":"Biostatistics Research Group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Husain","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Zangarini","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cranston","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stones","sequence":"additional","affiliation":[{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Bowett","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roblin","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Traversa","sequence":"additional","affiliation":[{"name":"Sienna Biopharmaceuticals, Inc, Colleretto Giacosa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Veal","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A. A.","family":"Langtry","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[{"name":"University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Burn","sequence":"additional","affiliation":[{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rajan","sequence":"additional","affiliation":[{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"doi180025r1","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S1470-2045(15)00245-4","article-title":"Inherited cylindromas: lessons from a rare tumour.","volume":"16","author":"Rajan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"doi180025r2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/archdermatol.2009.262","article-title":"Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.","volume":"145","author":"Rajan","year":"2009","journal-title":"Arch Dermatol"},{"issue":"41","key":"doi180025r3","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1038\/onc.2011.133","article-title":"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.","volume":"30","author":"Rajan","year":"2011","journal-title":"Oncogene"},{"issue":"19","key":"doi180025r4","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-08-0651","article-title":"On Trk\u2013the TrkB signal transduction pathway is an increasingly important target in cancer biology.","volume":"15","author":"Thiele","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"doi180025r5","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/carcin\/bgq180","article-title":"TrkC plays an essential role in breast tumor growth and metastasis.","volume":"31","author":"Jin","year":"2010","journal-title":"Carcinogenesis"},{"issue":"32","key":"doi180025r6","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1038\/onc.2012.377","article-title":"TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.","volume":"32","author":"Ivanov","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"doi180025r7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer.","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"issue":"5","key":"doi180025r8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2340\/00015555-2047","article-title":"Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis.","volume":"95","author":"Roblin","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"doi180025r10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13063-017-1812-z","article-title":"Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.","volume":"18","author":"Cranston","year":"2017","journal-title":"Trials"},{"issue":"3","key":"doi180025r11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-3565(25)08751-8","article-title":"Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes.","volume":"82","author":"Draize","year":"1944","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"doi180025r12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Sample size tables for exact single-stage phase II designs.","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat Med"},{"issue":"8","key":"doi180025r13","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/jid.2011.48","article-title":"Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor.","volume":"131","author":"Skvara","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi180025r14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi180025r15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol: a new facility for the measurement of health-related quality of life.","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"3","key":"doi180025r16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archderm.1956.01550030001001","article-title":"Eccrine spiradenoma.","volume":"73","author":"Kersting","year":"1956","journal-title":"AMA Arch Derm"},{"issue":"2","key":"doi180025r17","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"issue":"8","key":"doi180025r18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children.","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"2, pt 2","key":"doi180025r19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/0190-9622(93)70039-V","article-title":"Painful tumors of the skin: \u201cLEND AN EGG.\u201d","volume":"28","author":"Naversen","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"doi180025r9","volume-title":"Investigator\u2019s Brochure: Pegcantratinib","author":"Creabilis","year":"2015"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2684787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:15:57Z","timestamp":1751714157000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.1610"}},"subtitle":["The TRAC Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.1610","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}